Clinical Trial Update: EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial of EN3285 for preventing or delaying oral mucositis in head and neck cancer patients has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Oral Mucositis

Drugs mentioned

• EN3285

Snippet

Sponsor: Endo Pharmaceuticals | Conditions: Oral Mucositis, Head and Neck Cancer | Phase 3 | Status: TERMINATED